Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Robeco Institutional Asset Management B.V.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Robeco Institutional Asset Management B.V.
Robeco Institutional Asset Management B.V. cut its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating) by 15.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,450 shares of the biotechnology company's stock after selling 4,512 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Corcept Therapeutics were worth $626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
根据美国证券交易委员会(纳斯达克)的最新披露，Robeco机构资产管理公司在第三季度将其持有的Corcept Treateutics Inc.(美国证券交易委员会：CORT-GET评级)的股票削减了15.6%。该公司在此期间出售了4,512股后，拥有24,450股这家生物技术公司的股票。截至最近提交给美国证券交易委员会(美国证券交易委员会)的文件，Robeco机构资产管理公司在Corcept Treateutics持有的股份价值626,000美元。
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in Corcept Therapeutics by 2.5% during the first quarter. BlackRock Inc. now owns 15,424,767 shares of the biotechnology company's stock valued at $347,366,000 after purchasing an additional 376,774 shares during the period. Renaissance Technologies LLC lifted its position in Corcept Therapeutics by 0.8% during the second quarter. Renaissance Technologies LLC now owns 7,833,871 shares of the biotechnology company's stock valued at $186,289,000 after purchasing an additional 63,355 shares during the period. Federated Hermes Inc. lifted its position in Corcept Therapeutics by 16.8% during the second quarter. Federated Hermes Inc. now owns 5,537,000 shares of the biotechnology company's stock valued at $131,670,000 after purchasing an additional 796,580 shares during the period. State Street Corp lifted its position in Corcept Therapeutics by 2.6% during the second quarter. State Street Corp now owns 3,499,446 shares of the biotechnology company's stock valued at $83,217,000 after purchasing an additional 89,888 shares during the period. Finally, Parallel Advisors LLC lifted its position in Corcept Therapeutics by 39.8% during the second quarter. Parallel Advisors LLC now owns 2,718,328 shares of the biotechnology company's stock valued at $64,642,000 after purchasing an additional 774,009 shares during the period. 80.08% of the stock is currently owned by institutional investors and hedge funds.
其他一些机构投资者和对冲基金最近也增持或减持了该业务的股份。贝莱德股份有限公司在第一季度将其在Corcept Treateutics的持仓提高了2.5%。贝莱德股份有限公司目前持有这家生物技术公司15,424,767股股票，价值347,366,000美元，在此期间又购买了376,774股。文艺复兴技术有限责任公司在第二季度将其在Corcept治疗公司的头寸提高了0.8%。复兴科技有限责任公司现在拥有这家生物技术公司7833,871股股票，价值186,289,000美元，在此期间又购买了63,355股。联合爱马仕公司在第二季度将其在Corcept Treateutics的头寸提高了16.8%。联合爱马仕公司目前持有这家生物技术公司5,537,000股股票，价值131,670,000美元，在此期间又购买了796,580股。道富集团在第二季度将其在Corcept Treateutics的头寸提高了2.6%。道富集团目前持有这家生物技术公司3,499,446股股票，价值83,217,000美元，在此期间又购买了89,888股。最后，Parly Advisors LLC在第二季度将其在Corcept Treateutics的地位提高了39.8%。在此期间，Parly Advisors LLC又购买了774,009股，现在拥有2,718,328股这家生物技术公司的股票，价值64,642,000美元。80.08%的股票目前由机构投资者和对冲基金持有。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of research firms recently issued reports on CORT. StockNews.com upgraded shares of Corcept Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, December 27th. HC Wainwright cut their price objective on shares of Corcept Therapeutics from $33.00 to $30.00 and set a "buy" rating for the company in a report on Friday, December 9th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $31.25.
一些研究公司最近发布了关于CORT的报告。在12月27日(星期二)的一份研究报告中，StockNews.com将Corcept Treateutics的股票评级从“买入”上调至“强力买入”。HC Wainwright将Corcept治疗公司的股票目标价从33.00美元下调至30.00美元，并在12月9日星期五的一份报告中为该公司设定了“买入”评级。一位分析师对该股的评级为持有，三位分析师给出了买入评级，一位分析师给出了强烈的买入评级。根据MarketBeat.com的数据，该股目前的共识评级为买入，共识目标价为31.25美元。
Insider Transactions at Corcept Therapeutics
Corcept治疗公司的内幕交易
Corcept Therapeutics Stock Performance
Corcept Treateutics股票业绩
CORT opened at $22.44 on Friday. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of 22.44 and a beta of 0.60. The company has a fifty day moving average of $22.87 and a two-hundred day moving average of $25.49. Corcept Therapeutics Incorporated has a fifty-two week low of $16.47 and a fifty-two week high of $30.14.
Cort上周五开盘报22.44美元。该股市值24.2亿美元，市盈率22.44倍，贝塔系数0.60。该公司的50日移动均线切入位在22.87美元，200日移动均线切入位在25.49美元。Corcept Treateutics Inc.的股价为52周低点16.47美元，52周高点为30.14美元。
Corcept Therapeutics (NASDAQ:CORT – Get Rating) last released its earnings results on Thursday, November 3rd. The biotechnology company reported $0.30 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.07. The business had revenue of $101.73 million during the quarter, compared to analysts' expectations of $107.73 million. Corcept Therapeutics had a net margin of 29.37% and a return on equity of 27.49%. On average, equities research analysts forecast that Corcept Therapeutics Incorporated will post 0.89 earnings per share for the current year.
科塞特治疗公司(纳斯达克代码：CORT-GET评级)最近一次公布财报是在11月3日星期四。这家生物技术公司公布本季度每股收益为0.30美元，比分析师普遍预期的0.23美元高出0.07美元。该业务当季营收为1.0173亿美元，高于分析师预期的1.0773亿美元。Corcept Treeutics的净利润率为29.37%，股本回报率为27.49%。平均而言，股票研究分析师预测，Corcept治疗公司本年度的每股收益将为0.89美元。
Corcept Therapeutics Profile
Corcept Treateutics简介
(Get Rating)
(获取评级)
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
Corcept Treateutics公司在美国发现、开发和销售治疗严重代谢、肿瘤和神经精神疾病的药物。该公司提供Korlym(米非司酮)片剂，作为每日一次的口服药物，用于治疗患有内源性库欣综合征的成年患者继发于高皮质醇血症的高血糖，这些患者患有2型糖尿病或葡萄糖耐受不良，且手术失败或不适合手术。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Corcept Therapeutics (CORT)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
- 免费获取StockNews.com关于Corcept治疗(CORT)的研究报告
- MarketBeat：回顾中的一周01/09-01/13
- 摩根大通破产，银行为衰退做好准备
- 为什么Bed Bath&Beyond的股价上涨了261%？
- Roku股价走势，原因如下
- Carvana Stock Rally，这是你需要知道的
Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating).
想看看其他对冲基金持有Cort的股票吗？访问HoldingsChannel.com获取Corcept Treateutics Inc.(纳斯达克：CORT-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Corcept治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Corcept Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。